

Global Allogeneic T Cell Therapies Market Report and Forecast 2024-2032

Market Report | 2023-09-05 | 160 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2999.00
- Five User License \$3999.00
- Corporate License \$5999.00

Report description:

Global Allogeneic T Cell Therapies Market Report and Forecast 2024-2032

Global Allogeneic T-Cell Therapies Market Outlook

The growth of the global allogeneic T cell therapies market size is being driven by the increasing interest of pharmaceutical companies across the globe. The market size is anticipated to grow at a CAGR of 9.8% during the forecast period of 2024-2032.

Allogeneic T Cell Therapies: Introduction

Allogeneic T cell therapies are a type of immunotherapy that harnesses the power of T cells from healthy donors to treat various diseases, particularly cancer. T cells, a type of white blood cells, play a central role in the immune system's response to foreign substances, such as cancer cells or pathogens. Allogeneic T cell therapies involve isolating T cells from healthy donors, modifying them to enhance their anti-cancer activity, and then infusing them into patients to target and destroy cancer cells.

Allogeneic T cell therapies have shown promising results in the treatment of various haematological malignancies, including leukaemia, lymphoma, and multiple myeloma. They are also being investigated for solid tumours and other diseases, such as viral infections and autoimmune disorders. Ongoing research aims to optimize their efficacy, safety, and applicability to a broader range of diseases.

Key Trends in the Global Allogeneic T Cell TherapiesMarket

Key trends in the allogeneic T cell therapies market:

- **Advancements in Genetic Engineering:** The field of genetic engineering is rapidly evolving, and there are ongoing efforts to enhance the anti-cancer properties of allogeneic T-cell therapies. Researchers are exploring novel gene-editing techniques, such as CRISPR/Cas9, to precisely modify T cells and improve their efficacy and safety profiles.
- **Expansion into Solid Tumours:** While allogeneic T cell therapies have shown remarkable success in hematological malignancies, there is a growing focus on expanding their applications to solid tumors. Researchers are working on identifying suitable target antigens and developing strategies to overcome the challenges associated with the tumor microenvironment.
- **Combination Therapies:** Combining allogeneic T-cell therapies with other treatment modalities, such as immune checkpoint inhibitors, targeted therapies, or radiation, is gaining attention. Combination therapies have the potential to enhance the effectiveness of allogeneic T-cell therapies by promoting a synergistic anti-cancer immune response. Clinical trials evaluating the safety and efficacy of combination approaches are ongoing, and positive results could lead to the development of more effective

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

treatment regimens.

-□ Scalable Manufacturing Processes: With the increasing demand for allogeneic T-cell therapies, there is a need for scalable and cost-effective manufacturing processes. Researchers and companies are focusing on developing efficient manufacturing strategies that can produce large quantities of consistent and high-quality allogeneic T-cell products.

-□ Expansion of Clinical Trials: The number of clinical trials investigating allogeneic T-cell therapies is rapidly expanding. These trials aim to evaluate the safety, efficacy, and long-term outcomes of these therapies in different cancer types and patient populations. Additionally, clinical trials are exploring the use of allogeneic T-cell therapies in combination with other treatments or as a follow-up therapy after stem cell transplantation.

Global Allogeneic T Cell Therapies Market Segmentations

The market can be categorized into product type, therapeutics indications, end user, and region.

Market Breakup by Product Type

- Chimeric Antigen Receptor (CAR) T Cell Therapies
- T Cell Receptor (TCR) Therapies
- Others

Market Breakup by Therapeutics Indications

- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Others

Market Breakup by End User

- Hospitals
- Speciality Clinics
- Research Institutes
- Others

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Global Allogeneic T Cell Therapies Market Overview

The market for allogeneic T-cell therapies is experiencing substantial growth. The increasing prevalence of cancer and the demand for more effective treatment options are driving the market expansion. The market is expected to witness significant investments in research and development, manufacturing infrastructure, and commercialization activities. The allogeneic T cell therapies market is becoming increasingly competitive, with several biotechnology and pharmaceutical companies actively participating in research and development. Companies are striving to establish a competitive edge through innovative technologies, partnerships, and therapeutic advancements.

As allogeneic T cell therapies approach commercialization, access and affordability are significant considerations. The high costs of these therapies raise concerns about equitable access for patients. Payers and healthcare systems are grappling with reimbursement models that ensure patient access to these novel and potentially life-saving treatments. In summary, the allogeneic T cell therapies market is witnessing rapid growth and remarkable progress in the treatment of various cancers. Ongoing research, technological advancements, and regulatory developments will play pivotal roles.

Key Players in the Global Allogeneic T Cell Therapies Market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the allogeneic T cell therapies market are as follows:

- Athersys Inc.
- Mesoblast Ltd.
- Biorestorative Therapies Inc.
- Pluristem Inc.
- Brainstorm Cell Limited.
- ViaCyte Inc.
- Gamida Cell
- HOPE BIOSCIENCES
- Cellular Biomedicine Group
- Smith+Nephew
- MEDIPOST
- ANTEROGEN.CO, LTD.
- NuVasive Inc.
- RTI Surgical
- AlloSource
- CR Pharmaceuticals Co. Ltd.
- Takeda Pharmaceutical Company Limited

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1Preface
- 1.1Objectives of the Study
- 1.2Key Assumptions
- 1.3Report Coverage - Key Segmentation and Scope
- 1.4Research Methodology
- 2Executive Summary
- 3Global Allogeneic T Cell Therapies Market Overview
- 3.1Global Allogeneic T Cell Therapies Market Historical Value (2017-2023)
- 3.2Global Allogeneic T Cell Therapies Market Forecast Value (2024-2032)
- 4Global Allogeneic T Cell Therapies Market Landscape
- 4.1Global Allogeneic T Cell Therapies Developers Landscape
- 4.1.1Analysis by Year of Establishment
- 4.1.2Analysis by Company Size
- 4.1.3Analysis by Region
- 4.2Global Allogeneic T Cell Therapies Product Landscape
- 4.2.1Analysis by Product Type
- 4.2.2Analysis by Indications
- 4.2.3Analysis by End User
- 5Global Allogeneic T Cell Therapies Market Dynamics
- 5.1Market Drivers and Constraints
- 5.2SWOT Analysis
- 5.3Porter's Five Forces Model

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.4Key Demand Indicators
- 5.5Key Price Indicators
- 5.6Industry Events, Initiatives, and Trends
- 5.7Value Chain Analysis
- 6Global Allogeneic T Cell Therapies Market Segmentation
 - 6.1Global Allogeneic T Cell Therapies Market by Product Type
 - 6.1.1Market Overview
 - 6.1.2Chimeric Antigen Receptor (CAR) T Cell Therapies
 - 6.1.3T Cell Receptor (TCR) Therapies
 - 6.1.4Others
 - 6.2Global Allogeneic T Cell Therapies Market by Therapeutics Indications
 - 6.2.1Market Overview
 - 6.2.2Cancer
 - 6.2.3Autoimmune Diseases
 - 6.2.4Infectious Diseases
 - 6.2.5Others
 - 6.3Global Allogeneic T Cell Therapies Market by End User
 - 6.3.1Market Overview
 - 6.3.2Hospitals
 - 6.3.3Specialty Clinics
 - 6.3.4Research Institutes
 - 6.3.5Others
 - 6.4Global Allogeneic T Cell Therapies Market by Region
 - 6.4.1Market Overview
 - 6.4.2North America
 - 6.4.3Europe
 - 6.4.4Asia Pacific
 - 6.4.5Latin America
 - 6.4.6Middle East and Africa
- 7North America Allogeneic T Cell Therapies Market
 - 7.1Market Share by Country
 - 7.2United States of America
 - 7.3Canada
- 8Europe Allogeneic T Cell Therapies Market
 - 8.1Market Share by Country
 - 8.2United Kingdom
 - 8.3Germany
 - 8.4France
 - 8.5Italy
 - 8.6Others
- 9Asia Pacific Allogeneic T Cell Therapies Market
 - 9.1Market Share by Country
 - 9.2China
 - 9.3Japan
 - 9.4India
 - 9.5ASEAN
 - 9.6Australia

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.7Others
- 10Latin America Allogeneic T Cell Therapies Market
 - 10.1Market Share by Country
 - 10.2Brazil
 - 10.3Argentina
 - 10.4Mexico
 - 10.5Others
- 11Middle East and Africa Allogeneic T Cell Therapies Market
 - 11.1Market Share by Country
 - 11.2Saudi Arabia
 - 11.3United Arab Emirates
 - 11.4Nigeria
 - 11.5South Africa
 - 11.6Others
- 12Patent Analysis
 - 12.1Analysis by Type of Patent
 - 12.2Analysis by Publication year
 - 12.3Analysis by Issuing Authority
 - 12.4Analysis by Patent Age
 - 12.5Analysis by CPC Analysis
 - 12.6Analysis by Patent Valuation
 - 12.7Analysis by Key Players
- 13Grants Analysis
 - 13.1Analysis by year
 - 13.2Analysis by Amount Awarded
 - 13.3Analysis by Issuing Authority
 - 13.4Analysis by Grant Application
 - 13.5Analysis by Funding Institute
 - 13.6Analysis by NIH Departments
 - 13.7Analysis by Recipient Organization
- 14Funding Analysis
 - 14.1Analysis by Funding Instances
 - 14.2Analysis by Type of Funding
 - 14.3Analysis by Funding Amount
 - 14.4Analysis by Leading Players
 - 14.5Analysis by Leading Investors
 - 14.6Analysis by Geography
- 15Partnership and Collaborations Analysis
 - 15.1Analysis by Partnership Instances
 - 15.2Analysis by Type of Partnership
 - 15.3Analysis by Leading Players
 - 15.4Analysis by Geography
- 16Regulatory Framework
 - 16.1Regulatory Overview
 - 16.1.1US FDA
 - 16.1.2EU EMA
 - 16.1.3INDIA CDSCO

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.1.4JAPAN PMDA
- 16.1.5Others
- 17Supplier Landscape
 - 17.1Athersys Inc.
 - 17.1.1Financial Analysis
 - 17.1.2Product Portfolio
 - 17.1.3Demographic Reach and Achievements
 - 17.1.4Mergers and Acquisition
 - 17.1.5Certifications
 - 17.2Mesoblast Ltd.
 - 17.2.1Financial Analysis
 - 17.2.2Product Portfolio
 - 17.2.3Demographic Reach and Achievements
 - 17.2.4Mergers and Acquisition
 - 17.2.5Certifications
 - 17.3Biorestorative Therapies Inc.
 - 17.3.1Financial Analysis
 - 17.3.2Product Portfolio
 - 17.3.3Demographic Reach and Achievements
 - 17.3.4Mergers and Acquisition
 - 17.3.5Certifications
 - 17.4Pluristem Inc.
 - 17.4.1Financial Analysis
 - 17.4.2Product Portfolio
 - 17.4.3Demographic Reach and Achievements
 - 17.4.4Mergers and Acquisition
 - 17.4.5Certifications
 - 17.5Brainstorm Cell Limited.
 - 17.5.1Financial Analysis
 - 17.5.2Product Portfolio
 - 17.5.3Demographic Reach and Achievements
 - 17.5.4Mergers and Acquisition
 - 17.5.5Certifications
 - 17.6ViaCyte Inc.
 - 17.6.1Financial Analysis
 - 17.6.2Product Portfolio
 - 17.6.3Demographic Reach and Achievements
 - 17.6.4Mergers and Acquisition
 - 17.6.5Certifications
 - 17.7Gamida Cell
 - 17.7.1Financial Analysis
 - 17.7.2Product Portfolio
 - 17.7.3Demographic Reach and Achievements
 - 17.7.4Mergers and Acquisition
 - 17.7.5Certifications
 - 17.8HOPE BIOSCIENCES
 - 17.8.1Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.8.2Product Portfolio
17.8.3Demographic Reach and Achievements
17.8.4Mergers and Acquisition
17.8.5Certifications
17.9Cellular Biomedicine Group
17.9.1Financial Analysis
17.9.2Product Portfolio
17.9.3Demographic Reach and Achievements
17.9.4Mergers and Acquisition
17.9.5Certifications
17.10Smith+Nephew
17.10.1Financial Analysis
17.10.2Product Portfolio
17.10.3Demographic Reach and Achievements
17.10.4Mergers and Acquisition
17.10.5Certifications
17.11MEDIPOST
17.11.1Financial Analysis
17.11.2Product Portfolio
17.11.3Demographic Reach and Achievements
17.11.4Mergers and Acquisition
17.11.5Certifications
17.12ANTEROGEN.CO, LTD.
17.12.1Financial Analysis
17.12.2Product Portfolio
17.12.3Demographic Reach and Achievements
17.12.4Mergers and Acquisition
17.12.5Certifications
17.13NuVasive Inc.
17.13.1Financial Analysis
17.13.2Product Portfolio
17.13.3Demographic Reach and Achievements
17.13.4Mergers and Acquisition
17.13.5Certifications
17.14RTI Surgical
17.14.1Financial Analysis
17.14.2Product Portfolio
17.14.3Demographic Reach and Achievements
17.14.4Mergers and Acquisition
17.14.5Certifications
17.15AlloSource
17.15.1Financial Analysis
17.15.2Product Portfolio
17.15.3Demographic Reach and Achievements
17.15.4Mergers and Acquisition
17.15.5Certifications
17.16JCR Pharmaceuticals Co. Ltd.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.16.1Financial Analysis
- 17.16.2Product Portfolio
- 17.16.3Demographic Reach and Achievements
- 17.16.4Mergers and Acquisition
- 17.16.5Certifications
- 17.17Takeda Pharmaceutical Company Limited
- 17.17.1Financial Analysis
- 17.17.2Product Portfolio
- 17.17.3Demographic Reach and Achievements
- 17.17.4Mergers and Acquisition
- 17.17.5Certifications
- 18Global Allogeneic T Cell Therapies Market - Distribution Model (Additional Insight)
- 18.1Overview
- 18.2Potential Distributors
- 18.3Key Parameters for Distribution Partner Assessment
- 19Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20Company Competitiveness Analysis (Additional Insight)
- 20.1Very Small Companies
- 20.2Small Companies
- 20.3Mid-Sized Companies
- 20.4Large Companies
- 20.5Very Large Companies
- 21Payment Methods (Additional Insight)
- 21.1Government Funded
- 21.2Private Insurance
- 21.3Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Allogeneic T Cell Therapies Market Report and Forecast 2024-2032

Market Report | 2023-09-05 | 160 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$2999.00
	Five User License	\$3999.00
	Corporate License	\$5999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-03"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com